PRA Health Sciences, Inc. (NASDAQ:PRAH) – Equities research analysts at SunTrust Banks issued their FY2017 earnings per share estimates for PRA Health Sciences in a report issued on Monday. SunTrust Banks analyst S. Draper forecasts that the medical research company will earn $3.19 per share for the year. SunTrust Banks has a “Buy” rating and a $101.00 price target on the stock. SunTrust Banks also issued estimates for PRA Health Sciences’ Q4 2017 earnings at $0.98 EPS, FY2018 earnings at $3.98 EPS and FY2019 earnings at $4.82 EPS.

Several other research analysts have also commented on PRAH. Raymond James Financial, Inc. initiated coverage on shares of PRA Health Sciences in a research note on Wednesday, August 16th. They set an “outperform” rating and a $89.00 price objective for the company. Robert W. Baird increased their price objective on shares of PRA Health Sciences from $82.00 to $83.00 and gave the stock an “outperform” rating in a research note on Tuesday, August 8th. BidaskClub lowered shares of PRA Health Sciences from a “strong-buy” rating to a “buy” rating in a research note on Monday, July 31st. Credit Suisse Group increased their price objective on shares of PRA Health Sciences from $80.00 to $84.00 and gave the stock an “outperform” rating in a research note on Tuesday, August 8th. Finally, Zacks Investment Research downgraded shares of PRA Health Sciences from a “buy” rating to a “hold” rating in a report on Thursday, September 7th. One equities research analyst has rated the stock with a hold rating and twelve have assigned a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus target price of $88.09.

WARNING: “PRA Health Sciences, Inc. (PRAH) to Post FY2017 Earnings of $3.19 Per Share, SunTrust Banks Forecasts” was published by American Banking News and is the sole property of of American Banking News. If you are reading this piece on another website, it was illegally stolen and reposted in violation of United States and international copyright laws. The original version of this piece can be accessed at https://www.americanbankingnews.com/2017/11/02/pra-health-sciences-inc-prah-to-post-fy2017-earnings-of-3-19-per-share-suntrust-banks-forecasts.html.

PRA Health Sciences (NASDAQ:PRAH) last posted its earnings results on Wednesday, October 25th. The medical research company reported $0.88 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.85 by $0.03. The company had revenue of $494.55 million during the quarter, compared to analyst estimates of $477.89 million. PRA Health Sciences had a net margin of 5.64% and a return on equity of 21.66%. PRA Health Sciences’s revenue for the quarter was up 23.7% on a year-over-year basis. During the same period in the prior year, the business posted $0.64 earnings per share.

A number of institutional investors and hedge funds have recently bought and sold shares of PRAH. Zurcher Kantonalbank Zurich Cantonalbank grew its position in PRA Health Sciences by 12.0% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,488 shares of the medical research company’s stock valued at $112,000 after acquiring an additional 160 shares in the last quarter. Carroll Financial Associates Inc. boosted its stake in shares of PRA Health Sciences by 127.4% during the 3rd quarter. Carroll Financial Associates Inc. now owns 1,410 shares of the medical research company’s stock valued at $112,000 after buying an additional 790 shares during the last quarter. Meeder Asset Management Inc. boosted its stake in shares of PRA Health Sciences by 144.0% during the 2nd quarter. Meeder Asset Management Inc. now owns 1,535 shares of the medical research company’s stock valued at $115,000 after buying an additional 906 shares during the last quarter. Envestnet Asset Management Inc. boosted its stake in shares of PRA Health Sciences by 232.3% during the 1st quarter. Envestnet Asset Management Inc. now owns 1,844 shares of the medical research company’s stock valued at $121,000 after buying an additional 1,289 shares during the last quarter. Finally, CAPROCK Group Inc. purchased a new position in shares of PRA Health Sciences during the 2nd quarter valued at approximately $208,000. 98.48% of the stock is owned by hedge funds and other institutional investors.

In other news, major shareholder Pra Investors L.P. Kkr sold 9,500,000 shares of the company’s stock in a transaction dated Monday, August 14th. The shares were sold at an average price of $74.85, for a total transaction of $711,075,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Colin Shannon sold 400,000 shares of the company’s stock in a transaction dated Monday, August 14th. The shares were sold at an average price of $74.85, for a total transaction of $29,940,000.00. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 10,000,000 shares of company stock worth $748,500,000. 2.10% of the stock is owned by insiders.

About PRA Health Sciences

PRA Health Sciences, Inc is a contract research organization. The Company provides outsourced clinical development services to the biotechnology and pharmaceutical industries. The Company offers therapeutic services in areas of pharmaceutical development, including oncology, central nervous system, inflammation and infectious diseases.

Earnings History and Estimates for PRA Health Sciences (NASDAQ:PRAH)

Receive News & Ratings for PRA Health Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PRA Health Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.